The Transdermal Patch and the Vaginal Ring: Two Novel Methods of Combined Hormonal Contraception

2007 ◽  
Vol 34 (1) ◽  
pp. 31-42 ◽  
Author(s):  
Yael Swica
Keyword(s):  
Hormonal Contraception ◽  
Vaginal Ring ◽  
Transdermal Patch ◽  
Novel Methods ◽  
Combined Hormonal Contraception

Combined hormone contraceptive choice experience in Czech Republic

Open Medicine ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. 582-587 ◽  
Author(s):  
Tomas Fait
Keyword(s):  
Czech Republic ◽  
Hormonal Contraception ◽  
Vaginal Ring ◽  
Expert Advice ◽  
Hormonal Contraceptives ◽  
Application Form ◽  
Before And After ◽  
The Difference ◽  
Combined Hormonal Contraception ◽  
Combined Hormonal Contraceptives

AbstractThe aim of the prospective, multicenter project was to evaluate the effect of standardized information on the decision of woman when selecting application routes for combined hormonal contraceptives (CC). Selection the route of CC’s administration before and after consultation with the physician was evaluated on the group of 1326 women in 125 centres in the Czech Republic using a questionnaire. Analysis of the difference between the intended (4,1%) and selected (33,9%, CI 95% 31%–38%, 451 women) contraception shows that the vaginal ring preference increased by 29,8% (CI 97,5% 26,9%–32,8%, p < 0,0001). The difference for the weekly patch after (5,7%) and prior (4,2%) to the counseling of 1,4% was borderline statistically significant (CI 97,5%–0,002%–3,0%, p = 0,05). Preference of COC remained practically unchanged at 53,5%. Vaginal ring was selected by 45,2% of undecided women and 28,0% of women, who considered other than combined hormonal contraception. Easibility of application, efficacy and cycle control are the most important predictors for contraception choice. Following expert advice, including information on all forms of combined oral contraceptives, more than 33% of women chose the latest application form of combined hormonal contraceptives - vaginal ring.

Place of progestogenic oral contraceptives in gynecological practice

2019 ◽  
Vol 1 (1) ◽  
pp. 19-26
Author(s):  
I. V. Kuznetsova
Keyword(s):  
Venous Thrombosis ◽  
Oral Contraceptives ◽  
Hormonal Contraception ◽  
Review Of The Literature ◽  
Safety Issues ◽  
Routes Of Administration ◽  
Positive Effects ◽  
Combined Hormonal Contraception

The review of the literature presents data on the possible risks of using combined hormonal contraception and the possibilities of prescribing purely progestogenic contraception as an alternative to the use of combined means. Progestogen contraceptives include a group of agents with different routes of administration, doses and characteristics of progestins, which have a number of differences in the ratio of benefits and risks, availability, reversibility and other properties of contraception. Particular attention is paid to purely progestogenic tablets containing desogestrel, as a means equivalent in effectiveness to combination contraceptives, but safer. Safety issues are considered in the context of the use of breastfeeding women, as well as from the standpoint of the risk of arterial and venous thrombosis. The issues of non-contraceptive positive effects of purely progestogenic contraceptives are covered.

scholarly journals Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study

2021 ◽  
Author(s):  
Gabriele S. Merki-Feld ◽  
Peter S. Sandor ◽  
Rossella E. Nappi ◽  
Heiko Pohl ◽  
Christoph Schankin
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Natural Cycle ◽  
Free Interval ◽  
Migraine Frequency ◽  
Combined Hormonal Contraception ◽  
Migraine Onset

AbstractMany studies have described the features of menstrually related migraines but there is a lack of knowledge regarding the features of migraine in combined hormonal contraceptive users (CHC). Hormone-withdrawal migraines in the pill-free period could differ from those in the natural cycle. Gynaecologic comorbidities, like dysmenorrhea and endometriosis, but also depression or a family history might modify the course of migraine. A better understanding of migraine features linked to special hormonal situations could improve treatment. For this prospective cohort study, we conducted telephone interviews with women using a CHC and reporting withdrawal migraine to collect information on migraine frequency, intensity, triggers, symptoms, pain medication, gynaecologic history and comorbidities (n = 48). A subset of women agreed to also document their migraines in prospective diaries. The mean number of migraine days per cycle was 4.2 (± 2.7). Around 50% of these migraines occurred during the hormone-free interval. Migraine frequency was significantly higher in women who suffered from migraine before CHC start (5.0 ± 3.1) (n = 22) in comparison to those with migraine onset after CHC start (3.5 ± 2.1) (n = 26). Menstrually related attacks were described as more painful (57.5%), especially in women with migraine onset before CHC use (72%) (p < 0.02). Comorbidities were rare, except dysmenorrhea. The majority of migraine attacks in CHC users occur during the hormone-free interval. Similar as in the natural cycle, hormone-withdrawal migraines in CHC users are very intense and the response to acute medication is less good, especially in those women, who developed migraine before CHC use.

Estetrol and the possibilities of its clinical use

2021 ◽  
Vol 86 (3) ◽  
pp. 217-221
Author(s):  
Petr Křepelka ◽  
Keyword(s):  
Ethinyl Estradiol ◽  
Fetal Liver ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Cardiovascular Complications ◽  
Estradiol Valerate ◽  
Planned Parenthood ◽  
Menopausal Syndrome ◽  
Contraceptive Effectiveness ◽  
Combined Hormonal Contraception

Summary Combined hormonal contraceptive methods are one of the most commonly used methods of planned parenthood. They show high contraceptive effectiveness, reasonable cycle control and bring several non-contraceptive benefits. A limitation of the widespread use of combined hormonal contraception is the risk of cardiovascular complications in individuals with specific risk factors. The risk of cardiovascular complications is related to the used estrogen component. Currently, the most common use of estrogen in combined hormonal contraception is ethinyl estradiol and estradiol valerate. The good estrogenic part of combined oral contraceptives is estetrol, a hormone produced exclusively by the fetal liver. Estetrol exhibits a tissue-selective receptor activity. Unlike previously used estrogens, it does not negatively affect the production of liver proteins and blood clotting parameters. Estetrol is not a perspective for combined hormonal contraception only. It is also promising for treating and preventing osteoporosis, hormonal therapy of menopausal syndrome, and vulvovaginal atrophy syndrome.

scholarly journals Safety and Efficacy of Levonorgestrel 0.10 mg and Ethinyl Estradiol 0.02 mg plus Ethinyl Estradiol 0.01 mg in an Extended-Cycle Oral Contraceptive Regimen

2010 ◽  
Vol 2 ◽  
pp. CMT.S4661
Author(s):  
Radhika Rible ◽  
Ram Parvataneni ◽  
Angela Chen
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Pivotal Trial ◽  
Combined Oral Contraceptive ◽  
Free Interval ◽  
Effective Option ◽  
Effective Contraception ◽  
Combined Hormonal Contraception ◽  
Extended Cycle

Extended-cycle combined hormonal contraception has become a common practice among women seeking effective contraception and menstrual regulation. Extended cycle regimens have the benefit of decreasing scheduled bleeding as compared to traditional combined oral contraceptive (COC) regimens containing 21 days of hormones followed by a 7-day hormone-free interval (HFI) by reducing the frequency of the HFI. The newest FDA approved product in this family of contraceptive regimens is a 91-day COC regimen containing 0.02 mg ethinyl estradiol (EE) and 0.1 mg levonorgestrel (LNG) for 84 days followed by a 7-day interval with 0.01 mg EE. This regimen has been evaluated in one pivotal trial and demonstrated to have efficacy and a side effect profile similar to the other currently available FDA approved 91-day extended-cycle regimens. This is the first 91-day regimen formulated with 0.02 mg EE and offers women an effective option for contraception and menstrual cycle control.

Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy

2014 ◽  
Vol 112 (07) ◽  
pp. 73-78 ◽  
Author(s):  
Thomas Bergholt ◽  
Anne Nielsen ◽  
Michael J. Paidas ◽  
Ellen Christine L. Løkkegaard ◽  
Jesper Petersen
Keyword(s):  
Venous Thromboembolism ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
First Year ◽  
The Difference ◽  
Combined Hormonal Contraception ◽  
One Year ◽  
First Time ◽  
Combined Hormonal Contraceptives

SummaryEstimating the risk of venous thromboembolism (VTE) associated with combined hormonal contraceptives following early terminated pregnancies or birth, a Danish nationwide retrospective cohort observing a one-year follow-up was defined using three unique registries. All Danish women with confirmed pregnancies aged 15–49 during the period of 1995–2009 were included. The main outcomes were relative and absolute risks of first time venous thromboembolism in users as well as non-users of combined hormonal contraceptives. In 985,569 person-years, 598 venous thromboembolisms were recorded. After early terminated pregnancies and births, respectively, 113 and 485 events occurred in 212,552 and 773,017 person-years. After early terminated pregnancies, the crude VTE incidence ratios were similar, and the numbers needed to harm were equal between groups that did or did not use combined hormonal contraceptives throughout the follow-up year. After childbirth, individuals that used combined hormonal contraceptives were more likely than non-users to experience VTE depicted by crude incidence ratios; however, the difference was only significant after 14 weeks. This implied that the numbers needed to harm were lower for those that used compared to those that did not use combined oral contraceptives in the initial 14 weeks postpartum. In conclusion, the use of combined hormonal contraceptives after early terminated pregnancies was not detrimental, but during the puerperal period, they should be used with caution.

Managing the side effects of contraception

2021 ◽  
Vol 32 (6) ◽  
pp. 226-231
Author(s):  
Katie Boog
Keyword(s):  
Side Effects ◽  
Hormonal Contraception ◽  
Oral Contraceptive Pill ◽  
Common Reason ◽  
Evidence Based ◽  
Contraceptive Methods ◽  
Mood Change ◽  
Combined Oral Contraceptive ◽  
Free Interval ◽  
Combined Hormonal Contraception

Side effects are the most common reason for the discontinuation of contraceptive methods. Dr Katie Boog summarises the available evidence on how to manage them Although often transient, side effects are the most common reason for individuals to discontinue contraception. The evidence to prove causality is limited, as is evidence-based guidance on how to manage these side effects. This article summarises the available evidence. For individuals who have new or worsening acne on progestogen-only contraception (POC), switching to combined hormonal contraception (CHC) is likely to improve their skin. Continuous or extended CHC use may be beneficial for individuals with premenstrual mood change, and for those who experience headaches in the hormone-free interval. Unpredictable bleeding patterns on POC are common. Injectable users can try reducing the interval between injections to 10 weeks. Implant, injectable or intrauterine system users can be offered a 3-month trial of a combined oral contraceptive pill (COC). CHC and POP users with unpredictable bleeding may benefit from switching to an alternative preparation.

Sign in / Sign up

Export Citation Format

Share Document